Arndt-Christian Müller1, Birgitt van Oorschot2, Oliver Micke3, Matthias Guckenberger4. 1. Department of Radiation Oncology, Eberhard Karls University, Hoppe-Seyler-Str. 3, 72076, Tübingen, Deutschland. arndt-christian.mueller@med.uni-tuebingen.de. 2. Department of Radiation Oncology, Julius Maximilians University, Josef-Schneider-Str. 11, 97080, Würzburg, Deutschland. 3. Department of Radiotherapy and Radiation Oncology, Franziskus Hospital Bielefeld, Kiskerstraße 26, 33615, Bielefeld, Deutschland. 4. Department of Radiation Oncology, University of Zurich, Rämistrasse 100, 8001, Zürich, Schweiz.
Abstract
PURPOSE: We aim to introduce and discuss the statements and recommendations of the German S3 guideline on renal cell cancer for daily practice of radiation oncologists. METHODS: This report comprises indication, treatment decision, dose prescription and current literature including treatment of oligometastatic disease. RESULTS: According to different stages of the disease and the structure of the guideline we focus on five treatment situations and recommendations for decision making: (1) Neo-/adjuvant treatment before or after nephrectomy: No indication for radiotherapy. (2) Small renal mass: Stereotactic ablative radiotherapy is currently seen as experimental option due to small patient numbers reported in the literature. However, local tumor control achieved by SBRT appears favourable with >90% at 2 years. (3) Oligometastasis: Radiation treatment with higher local doses or stereotactic treatment is possible after interdisciplinary discussion. Indications for palliative (4) and symptomatic treatment (5) are not different compared to other tumor entities. CONCLUSION: Currently, there is no evidence-based indication for radiation treatment in the primary setting (adjuvant/neoadjuvant or definitive) of renal cell cancer. In the future stereotactic radiotherapy should have a stronger role in the treatment of medically inoperable patients with primary renal cell cancer and especially in the setting of oligometastasis.
PURPOSE: We aim to introduce and discuss the statements and recommendations of the German S3 guideline on renal cell cancer for daily practice of radiation oncologists. METHODS: This report comprises indication, treatment decision, dose prescription and current literature including treatment of oligometastatic disease. RESULTS: According to different stages of the disease and the structure of the guideline we focus on five treatment situations and recommendations for decision making: (1) Neo-/adjuvant treatment before or after nephrectomy: No indication for radiotherapy. (2) Small renal mass: Stereotactic ablative radiotherapy is currently seen as experimental option due to small patient numbers reported in the literature. However, local tumor control achieved by SBRT appears favourable with >90% at 2 years. (3) Oligometastasis: Radiation treatment with higher local doses or stereotactic treatment is possible after interdisciplinary discussion. Indications for palliative (4) and symptomatic treatment (5) are not different compared to other tumor entities. CONCLUSION: Currently, there is no evidence-based indication for radiation treatment in the primary setting (adjuvant/neoadjuvant or definitive) of renal cell cancer. In the future stereotactic radiotherapy should have a stronger role in the treatment of medically inoperable patients with primary renal cell cancer and especially in the setting of oligometastasis.
Authors: Paul W Sperduto; Brian Berkey; Laurie E Gaspar; Minesh Mehta; Walter Curran Journal: Int J Radiat Oncol Biol Phys Date: 2007-10-10 Impact factor: 7.038
Authors: Simon S Lo; Achilles J Fakiris; Eric L Chang; Nina A Mayr; Jian Z Wang; Lech Papiez; Bin S Teh; Ronald C McGarry; Higinia R Cardenes; Robert D Timmerman Journal: Nat Rev Clin Oncol Date: 2009-12-08 Impact factor: 66.675
Authors: Matthias Guckenberger; Rainer J Klement; Michael Allgäuer; Nicolaus Andratschke; Oliver Blanck; Judit Boda-Heggemann; Karin Dieckmann; Marciana Duma; Iris Ernst; Ute Ganswindt; Peter Hass; Christoph Henkenberens; Richard Holy; Detlef Imhoff; Henning K Kahl; Robert Krempien; Fabian Lohaus; Ursula Nestle; Meinhard Nevinny-Stickel; Cordula Petersen; Sabine Semrau; Jan Streblow; Thomas G Wendt; Andrea Wittig; Michael Flentje; Florian Sterzing Journal: Radiother Oncol Date: 2015-09-15 Impact factor: 6.280
Authors: E M Noordijk; C J Vecht; H Haaxma-Reiche; G W Padberg; J H Voormolen; F H Hoekstra; J T Tans; N Lambooij; J A Metsaars; A R Wattendorff Journal: Int J Radiat Oncol Biol Phys Date: 1994-07-01 Impact factor: 7.038
Authors: Eric L Chang; Jeffrey S Wefel; Kenneth R Hess; Pamela K Allen; Frederick F Lang; David G Kornguth; Rebecca B Arbuckle; J Michael Swint; Almon S Shiu; Moshe H Maor; Christina A Meyers Journal: Lancet Oncol Date: 2009-10-02 Impact factor: 41.316
Authors: Steven N Kalkanis; Douglas Kondziolka; Laurie E Gaspar; Stuart H Burri; Anthony L Asher; Charles S Cobbs; Mario Ammirati; Paula D Robinson; David W Andrews; Jay S Loeffler; Michael McDermott; Minesh P Mehta; Tom Mikkelsen; Jeffrey J Olson; Nina A Paleologos; Roy A Patchell; Timothy C Ryken; Mark E Linskey Journal: J Neurooncol Date: 2009-12-04 Impact factor: 4.130
Authors: S G C Kroeze; C Fritz; L Basler; E Gkika; T B Brunner; A L Grosu; M Guckenberger Journal: Strahlenther Onkol Date: 2019-02-08 Impact factor: 3.621